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The SMAC mimetic LCL-161 selectively 
targets  JAK2V617F mutant cells
Brianna M. Craver1, Thanh Kim Nguyen1, Jenny Nguyen1, Hellen Nguyen1, Christy Huynh1, Sarah J. Morse1 
and Angela G. Fleischman1,2,3* 
Abstract 
Background: Evasion from programmed cell death is a hallmark of cancer and can be achieved in cancer cells by 
overexpression of inhibitor of apoptosis proteins (IAPs). Second mitochondria-derived activator of caspases (SMAC) 
directly bind to IAPs and promote apoptosis; thus, SMAC mimetics have been investigated in a variety of cancer types. 
particularly in diseases with high inflammation and NFĸB activation. Given that elevated TNFα levels and NFĸB activa-
tion is a characteristic feature of myeloproliferative neoplasms (MPN), we investigated the effect of the SMAC mimetic 
LCL-161 on MPN cell survival in vitro and disease development in vivo.
Methods: To investigate the effect of the SMAC mimetic LCL-161 in vitro, we utilized murine and human cell lines 
to perform cell viability assays as well as primary bone marrow from mice or humans with  JAK2V617F–driven MPN 
to interrogate myeloid colony formation. To elucidate the effect of the SMAC mimetic LCL-161 in vivo, we treated a 
 JAK2V617F–driven mouse model of MPN with LCL-161 then assessed blood counts, splenomegaly, and myelofibrosis.
Results: We found that  JAK2V617F-mutated cells are hypersensitive to the SMAC mimetic LCL-161 in the absence of 
exogenous TNFα. JAK2 kinase activity and NFĸB activation is required for  JAK2V617F-mediated sensitivity to LCL-161, as 
JAK or NFĸB inhibitors diminished the differential sensitivity of  JAK2V617F mutant cells to IAP inhibition. Finally, LCL-161 
reduces splenomegaly and may reduce fibrosis in a mouse model of  JAK2V617F-driven MPN.
Conclusion: LCL-161 may be therapeutically useful in MPN, in particular when exogenous TNFα signaling is blocked. 
NFĸB activation is a characteristic feature of  JAK2V617F mutant cells and this sensitizes them to SMAC mimetic induced 
killing even in the absence of TNFα. However, when exogenous TNFα is added, NFĸB is activated in both mutant and 
wild-type cells, abolishing the differential sensitivity. Moreover, JAK kinase activity is required for the differential sensi-
tivity of  JAK2V617F mutant cells, suggesting that the addition of JAK2 inhibitors to SMAC mimetics would detract from 
the ability of SMAC mimetics to selectively target  JAK2V617F mutant cells. Instead, combination therapy with other 
agents that reduce inflammatory cytokines but preserve JAK2 signaling in mutant cells may be a more beneficial 
combination therapy in MPN.
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Background
Evasion of programmed cell death is a common survival 
technique utilized by cancer cells and one way these 
cells can evade apoptosis is by upregulating anti-apop-
totic proteins such as inhibitor of apoptosis proteins 
(IAPs) [1]. IAPs inhibit apoptosis by directly binding 
to and inhibiting pro-apoptotic caspases. However, 
when a cell is triggered to undergo apoptosis, second 
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mitochondria-derived activator of caspases (SMAC) is 
released into the cytosol and bind IAP proteins, leading 
to their degradation. Degradation of IAP proteins induces 
apoptosis by freeing pro-apoptotic caspases and allowing 
them to induce cell death. Small molecules which mimic 
the antagonistic effects of SMAC and lead to degradation 
of IAP proteins, termed SMAC mimetics, are actively 
being investigated in both hematologic malignancies and 
solid tumors [2, 3]. In preclinical studies, SMAC mimet-
ics induce apoptosis in cancer cells directly or indirectly 
by priming these cells for killing by other cytotoxic 
agents. SMAC mimetics sensitize cells to TNFα-induced 
cell death [4]. TNFα is a master regulator of inflamma-
tion and induces NFĸB activation among other signaling 
pathways. However, NFĸB activation is critical for SMAC 
mimetic-induced apoptosis [5]. In a study involving pri-
mary AML samples, sensitivity to a SMAC mimetic cor-
related with activation of TNF signaling and low XIAP 
expression [6]. Therefore, SMAC mimetics may be par-
ticularly useful in cancers associated with high inflamma-
tion and NFĸB activation.
Myeloproliferative neoplasm (MPN) is a chronic hema-
tologic malignancy characterized by chronic inflamma-
tion [7–9], high TNFα levels in serum [10], activation of 
NFĸB [11] and reduced expression of XIAP [12]. MPN is 
characterized by the somatic acquisition of a mutation in 
either JAK2 (JAK2V617F) [13–17] or calreticulin (CALR) 
[18, 19] in a hematopoietic stem cell. This mutant clone 
expands, producing excessive numbers of mature mye-
loid cells that also carry the driver mutation. The current 
goals of therapy in MPN are reduction of thrombotic 
risk, reduction in spleen volume, and alleviation of symp-
toms. There are no pharmacologic therapies currently in 
use apart from interferon-alpha that specifically deplete 
the neoplastic clone and lead to molecular remission [20]. 
Thus, there is an unmet need to identify therapeutics to 
successfully target JAK2V617F cells in MPN. The SMAC 
mimetic LCL-161 is currently in a Phase 2 clinical trials 
for the MPN subtype myelofibrosis (NCT02098161) [21]. 
However, it still remains unclear how LCL-161 impacts 
JAK2V617F or CALR mutant cells compared to wildtype 
counterparts.
Based upon the fact that there is hyperactivation of 
NFĸB signaling pathway [22] we reasoned that MPN cells 
would be more susceptible to killing by SMAC mimet-
ics. To test this, we performed cell viability assays using 
murine and human cell lines, myeloid colony formation 
assays using primary MPN patient cells and a mouse 
model to test the effect of the SMAC mimetic LCL-
161 on JAK2V617F cells in the presence and absence of 
TNFα. Here, we find that murine and human JAK2V617F 
cell lines are hypersensitive to the SMAC mimetic LCL-
161 in  vitro in the absence but not presence of TNFα. 
Furthermore, LCL-161 reduced myeloid colony forma-
tion to a greater extent in MPN mice and patients and 
reduced spleen size and possibly myelofibrosis in vivo.
Methods
Drug formulation
LCL-161 was provided by Novartis Pharmaceutical Cor-
poration. For in  vitro assays, LCL-161 was dissolved in 
DMSO at a concentration of 10  mM, stored in single 
use aliquots at − 80  °C, and dissolved directly in cul-
ture media fresh for each experiment. LCL-161 was for-
mulated for oral gavage by dissolving in 0.1 N HCl to a 
final concentration of 10 mg/ml in sodium acetate buffer 
(100  mM, pH 4.6). LCL-161 was prepared by first wet-
ting 10 mg powder stock with 30 μl water, and then dis-
solving in two equivalents (0.73 μl/mg of compound) of 
6.0 N HCl. The resulting (clear) solution was brought up 
to 1 ml in pH 4.6 acetate buffer, and the resulting stock 
was stored frozen at − 20 °C until used for gavage treat-
ment of mice.
Creation of L929 cell lines
Parental L929 cell line (ATCC ® CCL-1™, purchased 
from ATCC) were infected with retrovirus containing 
 JAK2WT,  JAK2V617F,  CALRDEL,  CALRWT, MPL, or empty 
vector containing green fluorescent protein (GFP) or 
human CD4 (hCD4) tags by spinoculation. GFP+ and/or 
hCD4+ cells were sorted on an Aria flow cytometer (BD) 
and expanded in culture.
Protein extraction and Western Blot
Following washes with PBS, cells were lysed in 1× 
Immunoprecipitation buffer (20  mM Tris–HCl pH 7.5, 
150  mM NaCl, 1  mM EDTA pH 8.0, 1  mM EGTA, 1% 
Triton X-100, 10  mM sodium pyrophosphate, 10  mM 
α-glycerophosphate, 1  mM  Na3VO4, and 50  mM NaF) 
by vortexing for 10 s and placing cells on ice for 10 min. 
Next, samples were centrifuged at 12,000×g for 15  min 
at 4°  C. Supernatants were collected and 4× Lamelli 
buffer (Bio-Rad) was added to each sample prior to stor-
age at − 20 °C. Protein concentration was determined by 
Bicinchoninic acid (BCA) assay at absorbance at 532 nm. 
Western blot analysis was performed using 30 µg for pro-
tein boiled for 10  min at 95  °C and electrophoresis was 
carried out on a 10% acrylamide gel. The protein was 
transferred onto a nitrocellulose membrane and blocked 
with 5% BSA in 0.1% PBS-T at 25  °C. The membrane 
was incubated for 1 h at room temperature or overnight 
at 4  °C with the primary antibodies for cIAP1 (ab2399, 
Abcam), cIAP2 (ab23423, Abcam), XIAP (ab28151, 
Abcam), and β-actin (ab8227, Abcam). Following three 
15  min wash steps with 0.1% PBS-T, membranes were 
incubated with secondary antibody goat-anti-rabbit 
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IgG for 1  h. Following an additional wash step, mem-
branes were imaged on a Chemdoc luminescence reader 
(Bio-Rad).
Human cell lines and apoptosis assays
K562 and HEL cells (gift from Brian Druker Lab, Oregon 
Health & Science University) were maintained in RPMI 
1640 (Corning) containing phenol red supplemented 
100  U penicillin, 100  µg/ml streptomycin, 2  mM glu-
tamine, and 10% FBS. Cells were cultured in a humidified 
tissue culture incubator at 37 °C and 5%  CO2. For apop-
tosis assays, K562 and HEL cells were plated into 12-well 
plates at a density of 1 × 106 cells per well in RPMI+ 10% 
FBS + Pen/Strep/l-glutamine containing vehicle, LCL-
161, or LCL-161 + TNFα. Following 16 h, flow cytometry 
for annexin-V and propidium iodide (PI) was performed.
Murine colony formation assays
Bone marrow was harvested from  JAK2V617F knock-in 
mouse model of MPN and cells were plated at a density 
of 10,000  cells/ml in Methocult M3230 (stem cell) sup-
plemented 10 ng/ml mouse interleukin-3 (mIL-3), 3 U/ml 
human erythropoietin (hEPO), and 50 ng/ml mouse stem 
cells factor (mSCF), all purchased from Peprotech. The 
cells were plated in triplicate at a density of 10,000 cells/
ml and incubated at 37 °C in a 5% carbon dioxide humidi-
fied incubator for 5–7 days. Standard morphological cri-
teria were used to score hematopoietic colonies using a 
light microscope.
Collection, isolation and culture of primary human samples
All participants gave their informed consent for the stud-
ies conducted in accordance with the Declaration of 
Helsinki. This study was approved by the Institutional 
Review Board of the University of California, Irvine 
(IRB HS #2014-9995). Peripheral blood samples were 
collected from MPN patients with Polycythemia Vera, 
Essential Thrombocytopenia, and Primary Myelofibrosis 
or normal controls. Density gradient centrifugation with 
Ficoll was performed to isolate blood mononuclear cells 
(PBMCs). Following PBMC isolation, a red blood cell 
lysis step was performed with ammonium chloride buffer 
(ACK).
Human hematopoietic colony assays
Isolated PBMCs were plated in Methocult H4320 (Stem 
Cell Technologies, Vancouver Canada) supplemented 
10  ng/ml human interleukin-3 (hIL-3), 3  U/ml human 
erythropoietin (hEPO), and 50  ng/ml human stem cells 
factor (hSCF). The cells were plated in triplicate at a 
density of 100,000  cells/ml and incubated at 37  °C in a 
5%  CO2 humidified incubator for 7–10  days. Standard 
morphological criteria were used to score hematopoietic 
colonies using a light microscope.
Mice
All mouse work was performed with approval from the 
IACUC committee at University of California, Irvine. 
Equal numbers of male and female mice were used for 
all experiments. The  Jak2V617F was a gift from Ann Mul-
lally, Brigham and Women’s Hospital. The transduction–
transplantation mouse model of  JAK2V617F driven-MPN 
was established as previously described [10, 23].
Statistics
All statistical analyses were performed using Graph-
pad Prism version 7.0 (Graphpad, La Jolla, CA, USA). 
Statistical analyses were performed using an unpaired 
t-test (Holm–Sidak) or 2way ANOVA (Tukey’s test). Sig-
nificant differences were indicated as *P < 0.05, **P < 0.01, 
***P < 0.001, ***P < 0.0001. Error bars represent mean 
values ± SEM. All experiments were performed at least 
three independent times unless otherwise stated.
Results
JAK2V617F mutant cells are hyper‑sensitive to the SMAC 
mimetic LCL‑161 in the absence but not presence of TNFα
To investigate the sensitivity of  JAK2V617F mutant cells to 
LCL-161, we created cell lines with stable expression of 
 JAK2V617F,  JAK2WT, or empty GFP vector by retroviral 
transduction. In this assay, we utilized the mouse fibro-
blast L929 line which are extremely sensitive to TNFα-
induced death. We measured the impact of increasing 
concentrations of LCL-161 on the viability of these 
cells using a resazurin based assay in the presence or 
absence of TNFα (Fig.  1a–c). Sub-micromolar concen-
trations of LCL-161 significantly reduced the viability 
of L929  JAK2V617F cells compared to  JAK2WT or empty 
vector cells (Fig.  1a). We observed 50% cell viability of 
L929  JAK2V617F cells with 0.45  µM LCL-161 as com-
pared to similar cell viabilities with 5.5  µM and 9.5  µM 
LCL-161 for empty vector or  JAK2WT cells, respectively 
(P < 0.0001, 2way ANOVA; Fig. 1a). However, this differ-
ential sensitivity was lost when TNFα was added to cul-
ture (Fig.  1b). Interestingly, overexpression of  JAK2WT 
rendered L929 cells resistant to killing by higher concen-
trations of LCL-161 in the presence of TNFα, as these 
cells were 50% viable in the presence of 19 µM LCL-161 
(P < 0.0001, 2way ANOVA; Fig. 1b).
Next, we assessed whether autonomous produc-
tion of TNFα could explain the increased sensitivity 
of  JAK2V617F cells to LCL-161. To do this, we tested 
whether TNFα neutralizing antibody abrogates the 
increased sensitivity of  JAK2V617F mutant L929 cells 
to LCL-161. Addition of TNFα neutralizing antibody 
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did not rescue the increased sensitivity of  JAK2V617F 
cells to LCL-161 (Fig.  1c) suggesting that the sensitiv-
ity of  JAK2V617F cells was not due to autonomous pro-
duction of TNFα. Moreover, we could not detect any 
TNFα in the supernatant of L929  JAK2V617F cells, either 
at baseline or with the addition of LCL-161 by ELISA 
(data not shown). As expected, treatment with LCL-161 
decreased both cIAP1 and cIAP2 (Fig.  1d). We found 
no marked differences in expression of cIAP1, cIAP2, 
or XIAP in  JAK2V617F versus  JAK2WT or parental L929 
cells under any conditions tested (Fig. 1d). However, we 
did find evidence that sensitivity to LCL-161 is medi-
ated at least in part to NFĸB activation, the NFĸB inhib-
itor QNZ had a protective effect on empty vector cells 
in the presence but not absence of TNF, whereas QNZ 
had a protective effect on  JAK2V617F mutant cells only 
in the absence of TNF (Additional file  1: Figure S1). 
This suggests that  JAK2V617F induces NFĸB activation in 
L929 cells and this mediates the sensitivity to LCL-161.
We also compared the ability of LCL-161 to induce 
apoptosis in the HEL human erythroleukemia cell line 
which harbors the JAK2V617F mutation versus the K562 
human erythroleukemia cell line which harbors the 
BCR-ABL translocation. LCL-161 induced apoptosis sig-
nificantly more in HEL cells as compared to K562 cells 
in the absence (P < 0.001, unpaired t test; Fig. 1e) but not 
presence of TNFα (Fig. 1f, g). Likewise, expression levels 
of cIAP1, cIAP2, or XIAP did not correlate with sensitiv-
ity to LCL-161 in HEL human cells expressing  JAK2V617F 
as compared to K562 cells (Additional file 1: Figure S2). 
These data in human cell lines corroborate our findings 
in L929 cells that  JAK2V617F mutant cells are more sensi-
tive to killing by LCL-161 alone, but when TNFα is added 
this differential sensitivity is lost.
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Fig. 1 JAK2V617F mutant cells lines are more sensitive to killing by LCL-161 under certain circumstances. a–c. L929 cells expressing  JAK2WT,  JAK2V617F 
or empty vector were incubated with increasing concentrations of a LCL-161 alone, b LCL-161 with the addition of 0.25 ng/ml mTNFα, c LCL-161 
with the addition of 400 ng/ml mTNFa neutralizing antibody for 48 h and then analyzed with a resazurin based viability assay. ****P < 0.0001, 2way 
ANOVA. d Western blot of L929 cell lines harvested 24 h after exposure to combinations of LCL-161 and mTNFα. e–g HEL and K562 cells were 
incubated with e LCL-161 alone, f LCL-161 + 1 ng/ml hTNFα, or g LCL-161 + 10 ng/ml hTNFα for 48 h. Apoptosis was measured with Annexin V and 
PI staining. **P < 0.01, ****P < 0.0001 unpaired t test
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Calreticulin mutated cells are not hyper‑sensitive 
to LCL‑161
To investigate the effect of LCL-161 on calreticu-
lin mutant cells, we also created L929 cell ectopically 
expressing MPN associated calreticulin (CALR) muta-
tions with and without its obligate cytokine receptor 
scaffold thrombopoietin receptor (MPL). CALR mutant 
L929 cells were not more sensitive to LCL-161 as com-
pared to empty vector either with or without co-expres-
sion of MPL (Additional file  1: Figure S3). Interestingly, 
overexpression of wild-type CALR led to increased sen-
sitivity to LCL-161 when co-expressed with MPL as com-
pared to cells with empty vector, CALR deletion or CALR 
insertion (Additional file 1: Figure S3).
Sensitivity of  JAK2V617F cells to LCL‑161 is dependent 
upon Janus kinase activity
To determine whether the increased sensitivity of 
 JAK2V617F cells to LCL-161 is dependent upon Janus 
kinase (JAK) activity, we utilized the JAK inhibitors 
ruxolitinib (JAK1/2 inhibitor) and pacritinib (JAK2/
Flt3 inhibitor) in a resazurin based cell viability assay. 
Sensitivity of  JAK2V617F L929 cells was dependent upon 
activation of JAK2 activity, as treatment with either rux-
olitinib or pacritinib reversed the increased sensitivity 
of  JAK2V617F cells to LCL-161 (Fig. 2). This data suggests 
that the hyper-sensitivity of  JAK2V617F cells to LCL-161 is 
due to constitutive JAK2 activation.
LCL‑161 reduces myeloid colony formation in  JAK2V617F 
knock‑in mice and MPN patient cells in the absence 
of TNFα
To investigate the effect of LCL-161 on myeloid col-
ony formation in primary mouse bone marrow cells, 
we performed colony formation assays from  JAK2V617F 
knock-in and wild-type mice with increasing concen-
trations of LCL-161. LCL-161 reduced colony forma-
tion in  JAK2V617F cells compared to wild-type cells in 
the presence of all doses tested, although only the 1 µM 
LCL-161 dose reached statistical significance (P < 0.001, 
unpaired t-test; Fig.  3a). However, the differential sen-
sitivity of  JAK2V617F cells was lost in the presence of 
TNFα (Fig.  3b). This data further supports the model 
that  JAK2V617F cells have increased sensitivity to SMAC 
mimetics in the absence but not presence of TNFα.
We next investigated the effect of LCL-161 on colony 
formation using primary cells from MPN patients com-
pared to unaffected individuals. In the presence of LCL-
161 alone, there was a reduction in colony formation 
from JAK2V617F mutated MPN patients versus normal 
controls at 1 µM and 2.5 µM doses, though this trend did 
not reach significance (P = 0.05 and 0.07, respectively, 
unpaired t test; Fig. 3c). These same trends were observed 
when erythroid and G/M colonies were enumerated sep-
arately (Additional file  1: Figure S4). When TNFα was 
added to the culture, this diminished the apparent differ-
ence between MPN and normal controls in response to 
LCL-161 at all but the highest concentration (5  µM) of 
LCL-161 (P < 0.05, unpaired t test; Fig. 3d).
LCL‑161 reduces spleen size and ameliorates fibrosis 
in a  JAK2V617F transduction–transplantation model
To test the efficacy of LCL-161 in  vivo, we utilized a 
 JAK2V617F transduction–transplantation MPN mouse 
model that develops myelofibrosis around 1  year of age 
[23–26]. Treatment with LCL-161 was initiated 15 weeks 
after transplant with twice weekly oral administration. 
We did not detect changes in peripheral blood counts 
nor percentage of GFP+ cells in the peripheral blood in 
LCL-treated mice compared to untreated mice (n = 3–4 
mice/group, Fig.  4a–e). However, at sacrifice we found 
that LCL-161 treatment significantly reduced spleen size 
(P < 0.05, unpaired t test; Fig.  4f ) and modestly reduced 
the percentage of GFP+ cells in the bone marrow and 
spleen of  JAK2V617F mice (n = 3–4 mice/group, Fig.  4g). 
Upon analysis of reticulin-stained bone marrows, we 
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Fig. 2 JAK inhibitors rescue hypersensitivity of  JAK2V617F mutant cells to LCL-161. L929 cells expressing  JAK2WT,  JAK2V617F or empty vector were 
incubated with increasing concentrations of a LCL-161 alone, b LCL-161 with the addition of 1 µM ruxolitinib, or c LCL-161 with the addition of 1 µM 
pacritinib. After 48 h in culture a resazurin-based cell viability assay was performed. ****P < 0.0001, 2way ANOVA
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observed that fibrosis was reduced in mice that had been 
treated with LCL-161 (Fig. 4h). These data demonstrate 
that LCL-161 may have a beneficial effect on an in vivo 
model of  JAK2V617F mutated MPN.
Discussion
Here, we found that mouse cell lines ectopically express-
ing  JAK2V617F, the JAK2V617F mutated human cell line 
HEL,  JAK2V617F knock-in mice, and primary MPN sam-
ples were more sensitive to killing by the SMAC mimetic 
LCL-161 compared to their  JAK2WT counterparts. 
Although addition of exogenous TNFα increased the sen-
sitivity of both mutant and wild-type cells to LCL-161, 
the differential sensitivity of mutant cells was abolished 
when TNFα was added to culture. The increased sensi-
tivity to LCL-161 was not due to autocrine production of 
TNFα, as pharmacologic blockade of TNFα did not res-
cue  JAK2V617F mutant cells from LCL-161.
Activation of JAK2 signaling is critical for the increased 
sensitivity of  JAK2V617F mutant cells to LCL-161. Addi-
tion of JAK2 inhibitors ruxolitinib or pacritinib restored 
LCL-161 sensitivity of  JAK2V617F mutant to that of 
wild-type cells. This observation suggests JAK2 inhibi-
tors may reduce the vulnerability of JAK2 mutant cells 
to be preferentially killed by SMAC mimetics and that 
therapeutic combinations of JAK2 inhibitors and SMAC 
mimetic in patients may not be an ideal combination. 
This is an important point given that it is common for 
new investigational agents in myelofibrosis to be tested in 
combination with ruxolitinib.
The ex  vivo experiments with mouse and primary 
human myeloid colony formation corroborate our find-
ings in cell lines that MPN mutant cells are more sensi-
tive than wild-type cells in the absence but not presence 
of TNFα. Human MPN patients have variable frequencies 
of  JAK2V617F and so our methylcellulose colony forma-
tion assays with primary MPN patient cells assess both 
mutant and wild-type colonies. This may explain why the 
impact of LCL-161 on MPN patient colony formation 
was less robust than our observations in cell lines bearing 
the  JAK2V617F mutation.
Cells bearing the MPN associated  CALRDEL mutation 
were not more sensitive to LCL-161 when expressed 
either with or without its obligate cytokine receptor 
scaffold MPL. This suggests that SMAC mimetics may 
be most beneficial in  JAK2V617F mutated MPN patients. 
CALR binds to and specifically activates MPL, whereas 
 JAK2V617F activates signaling of multiple cytokine 
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Fig. 3 LCL-161 preferentially decreases MPN colony formation. Methylcellulose colony formation of a, b whole bone marrow from  JAK2V617F 
or wild-type mice and c, d peripheral blood mononuclear cells from JAK2V617F mutated MPN patients or normal controls with increasing 
concentrations of LCL-161 alone (a, c) or LCL-161 + 0.25 ng/ml TNFα (b, d). *P < 0.05, ***P < 0.001, unpaired t test
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receptor pathways. The sensitivity of  JAK2V617F to 
SMAC mimetics is likely mediated via activation of 
pathways distinct from MPL. Therefore, combination 
therapy with SMAC mimetic and drugs which target 
MPL signaling may be additive or even synergistic in 
 JAK2V617F mutated MPN.
In our in  vivo mouse model, we found that LCL-
161 had modest effects on peripheral blood counts. 
Although LCL-161 did reduce the percentage of GFP+ 
cells in the spleen and bone marrow, these effects were 
modest and did not reach significance. The primary 
benefit of LCL-161 in this mouse model was reduc-
tion in splenomegaly and possible reduction of fibro-
sis. Future studies would require increasing numbers of 
mice to validate the effect of LCL-161 on splenomegaly 
and myelofibrosis in vivo. Regardless, our findings sug-
gest that LCL-161 may not be an ideal single agent in 
MPN but may be most useful as an adjunct to other 
MPN therapies.
Approaches that reduce TNFα but maintain constitu-
tive activation of JAK2 in mutant cells may be an ideal 
combination with SMAC mimetics in MPN. The TNFα 
decoy receptor etanercept has been investigated as a 
single agent in an open label pilot study in myelofibro-
sis and was found to alleviate symptoms [27]. Another 
potential approach as a combinatorial study with SMAC 
mimetics would be to combine with a JAK inhibitor that 
is devoid of JAK2 inhibitory activity, such as itacitinib 
(INCB039110). This would result in reduction of inflam-
matory cytokines including TNFα while preserving 
the vulnerability of  JAK2V617F cells to killing by SMAC 
mimetic.
Conclusion
SMAC mimetics may be useful in patients with  JAK2V617F 
mutated MPN, as  JAK2V617F mutant cells are more read-
ily killed by SMAC mimetics as compared to wild-type 
cells. This vulnerability to SMAC mimetics is mediated 
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via JAK2 activation, therefore addition of a JAK2 inhibi-
tor to SMAC mimetics may detract from the ability of 
SMAC mimetics to preferentially kill JAK2V617F mutant 
cells. However, therapy with agents that reduce or block 
TNFα may augment the ability of SMAC mimetics to 
specifically target JAK2V617F mutant cells.
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Supplementary information accompanies this paper at https ://doi.
org/10.1186/s4016 4-019-0157-6.
Additional file 1: Figure S1. NFĸB inhibitor protects JAK2V617F mutant 
cells from killing by LCL-161 in the absence of TNFα and empty vector cells 
from killing by LCL-161 in the presence of TNFα. L929 cell transduced with 
empty vector or  JAK2V617F were exposed to LCL-161, either in the presence 
or absence of 1 ng/ml hTNFα and 1nM QNZ. The concentration of LCL-161 
used without TNFα was 1.5 µM and with TNFα was 12.5 nM. After 48 h of 
culture a resazurin based cell viability assay was performed.
Additional file 2: Figure S2. Expression levels of cIAP1/2 or XIAP do not 
influence sensitivity of human cell lines to LCL-161. Western blot of K562 
(BCR-ABL mutant) and HEL  (JAK2V617F) cells treated with 10 nM LCL-161 
for 2 h before protein isolation. LCL-161 reduces expression of cIAP1 and 
cIAP2 in both cell lines as expected. XIAP expression was unaffected by 
LCL-161.
Additional file 3: Figure S3. Calreticulin-mutant cells are not hyper-
sensitive to LCL-161. (A, B) Resazurin-based cell viability assay showing 
L929 cells transduced with the Calreticulin (CALR) mutations represent-
ing empty vector (EV), wild-type CALR  (CALRWT), deletion  (CALRDEL) or 
insertion  (CALRINS) (A) containing thrombopoietin receptor (MPL) and (B) 
without MPL treated with increasing concentrations of LCL-161 for 48 h. 
**P < 0.01, ***P < 0.001 2way ANOVA. (C) Western blot for cIAP1/2, XIAP, 
and β-Actin as a loading control in  CALRWT,  CALRDEL,  CALRINS, or empty 
vector (VEH) cells in the presence or absence of MPL. (D) Myeloid colony 
formation using MNCs from normal controls (n = 5), CALR-mutated 
patients (n = 5), and  JAK2V617F patients (n = 5). Cells were plated in methyl-
cellulose with varying LCL-161 concentrations. Colonies were counted 
from each plate and normalized to 0 µM LCL-161. Error bar represent 
mean values ± SEM.
Additional file 4: Figure S4. Colony formation shown in Fig. 3 separated 
by erythroid and G/M colonies. (A) Erythroid and (B) G/M colony formation 
from MPN patients and normal controls with increasing concentrations of 
LCL-161. (C) Erythroid and (D) G/M colony formation from MPN patients 
and normal controls with 10 ng/ml TNFα + increasing concentrations of 
LCL-161.
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